817 related articles for article (PubMed ID: 18787055)
1. Metabolism of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737): identification of an unusual N-acetylglucosamine conjugate in the cynomolgus monkey.
Johnson BM; Kamath AV; Leet JE; Liu X; Bhide RS; Tejwani RW; Zhang Y; Qian L; Wei DD; Lombardo LJ; Shu YZ
Drug Metab Dispos; 2008 Dec; 36(12):2475-83. PubMed ID: 18787055
[TBL] [Abstract][Full Text] [Related]
2. Mechanistic studies on a P450-mediated rearrangement of BMS-690514: conversion of a pyrrolotriazine to a hydroxypyridotriazine.
Hong H; Caceres-Cortes J; Su H; Huang X; Roongta V; Bonacorsi S; Hong Y; Tian Y; Iyer RA; Humphreys WG; Christopher LJ
Chem Res Toxicol; 2011 Jan; 24(1):125-34. PubMed ID: 21080678
[TBL] [Abstract][Full Text] [Related]
3. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
4. Metabolism and disposition of [14C]BMS-690514 after oral administration to rats, rabbits, and dogs.
Hong H; Su H; Sun H; Allentoff A; Ekhato IV; Chando T; Caceres-Cortes J; Roongta V; Iyer RA; Humphreys WG; Christopher LJ
Drug Metab Dispos; 2010 Jul; 38(7):1189-201. PubMed ID: 20363952
[TBL] [Abstract][Full Text] [Related]
5. In vitro characterization of the metabolic pathways and cytochrome P450 inhibition and induction potential of BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor.
Hong H; Su H; Ma L; Yao M; Iyer RA; Humphreys WG; Christopher LJ
Drug Metab Dispos; 2011 Sep; 39(9):1658-67. PubMed ID: 21673131
[TBL] [Abstract][Full Text] [Related]
6. Metabolism and pharmacokinetics of a novel Src kinase inhibitor TG100435 ([7-(2,6-dichloro-phenyl)-5-methyl-benzo[1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine) and its active N-oxide metabolite TG100855 ([7-(2,6-dichloro-phenyl)-5-methylbenzo[1,2,4]triazin-3-yl]-{4-[2-(1-oxy-pyrrolidin-1-yl)-ethoxy]-phenyl}-amine).
Hu SX; Soll R; Yee S; Lohse DL; Kousba A; Zeng B; Yu X; McPherson A; Renick J; Cao J; Tabak A; Hood J; Doukas J; Noronha G; Martin M
Drug Metab Dispos; 2007 Jun; 35(6):929-36. PubMed ID: 17371799
[TBL] [Abstract][Full Text] [Related]
7. Metabolism of prazosin in rat, dog, and human liver microsomes and cryopreserved rat and human hepatocytes and characterization of metabolites by liquid chromatography/tandem mass spectrometry.
Erve JC; Vashishtha SC; DeMaio W; Talaat RE
Drug Metab Dispos; 2007 Jun; 35(6):908-16. PubMed ID: 17353349
[TBL] [Abstract][Full Text] [Related]
8. In vitro metabolism of 2-[6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl] acetic acid (licofelone, ML3000), an inhibitor of cyclooxygenase-1 and -2 and 5-lipoxygenase.
Albrecht W; Unger A; Nussler AK; Laufer S
Drug Metab Dispos; 2008 May; 36(5):894-903. PubMed ID: 18268076
[TBL] [Abstract][Full Text] [Related]
9. Biotransformation of 6-methoxy-3-(3',4',5'-trimethoxy-benzoyl)-1H-indole (BPR0L075), a novel antimicrotubule agent, by mouse, rat, dog, and human liver microsomes.
Yao HT; Wu YS; Chang YW; Hsieh HP; Chen WC; Lan SJ; Chen CT; Chao YS; Chang L; Sun HY; Yeh TK
Drug Metab Dispos; 2007 Jul; 35(7):1042-9. PubMed ID: 17403915
[TBL] [Abstract][Full Text] [Related]
10. Bioactivation of isothiazoles: minimizing the risk of potential toxicity in drug discovery.
Teffera Y; Choquette D; Liu J; Colletti AE; Hollis LS; Lin MH; Zhao Z
Chem Res Toxicol; 2010 Nov; 23(11):1743-52. PubMed ID: 20825217
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of ML3403 ({4-[5-(4-fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-(1-phenylethyl)-amine), a 4-Pyridinylimidazole-type p38 mitogen-activated protein kinase inhibitor.
Kammerer B; Scheible H; Albrecht W; Gleiter CH; Laufer S
Drug Metab Dispos; 2007 Jun; 35(6):875-83. PubMed ID: 17344341
[TBL] [Abstract][Full Text] [Related]
12. Metabolism and disposition of [14C]BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor, after oral administration to humans.
Christopher LJ; Hong H; Vakkalagadda BJ; Clemens PL; Su H; Roongta V; Allentoff A; Sun H; Heller K; Harbison CT; Iyer RA; Humphreys WG; Wong T; Zhang S
Drug Metab Dispos; 2010 Nov; 38(11):2049-59. PubMed ID: 20668249
[TBL] [Abstract][Full Text] [Related]
13. Metabolism, distribution and excretion of a selective N-methyl-D-aspartate receptor antagonist, traxoprodil, in rats and dogs.
Prakash C; Cui D; Potchoiba MJ; Butler T
Drug Metab Dispos; 2007 Aug; 35(8):1350-64. PubMed ID: 17496205
[TBL] [Abstract][Full Text] [Related]
14. Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737), an in vivo active potent VEGFR-2 inhibitor.
Ruel R; Thibeault C; L'Heureux A; Martel A; Cai ZW; Wei D; Qian L; Barrish JC; Mathur A; D'Arienzo C; Hunt JT; Kamath A; Marathe P; Zhang Y; Derbin G; Wautlet B; Mortillo S; Jeyaseelan R; Henley B; Tejwani R; Bhide RS; Trainor GL; Fargnoli J; Lombardo LJ
Bioorg Med Chem Lett; 2008 May; 18(9):2985-9. PubMed ID: 18395443
[TBL] [Abstract][Full Text] [Related]
15. Studies on the metabolism of the novel, selective cyclooxygenase-2 inhibitor indomethacin phenethylamide in rat, mouse, and human liver microsomes: identification of active metabolites.
Remmel RP; Crews BC; Kozak KR; Kalgutkar AS; Marnett LJ
Drug Metab Dispos; 2004 Jan; 32(1):113-22. PubMed ID: 14709628
[TBL] [Abstract][Full Text] [Related]
16. Biotransformation of the anti-angiogenic compound SU5416.
Antonian L; Zhang H; Yang C; Wagner G; Shawver LK; Shet M; Ogilvie B; Madan A; Parkinson A
Drug Metab Dispos; 2000 Dec; 28(12):1505-12. PubMed ID: 11095590
[TBL] [Abstract][Full Text] [Related]
17. Metabolic profile of FYX-051 (4-(5-pyridin-4-yl-1h-[1,2,4]triazol-3-yl)pyridine-2-carbonitrile) in the rat, dog, monkey, and human: identification of N-glucuronides and N-glucosides.
Nakazawa T; Miyata K; Omura K; Iwanaga T; Nagata O
Drug Metab Dispos; 2006 Nov; 34(11):1880-6. PubMed ID: 16914512
[TBL] [Abstract][Full Text] [Related]
18. In vitro hepatic metabolism of cediranib, a potent vascular endothelial growth factor tyrosine kinase inhibitor: interspecies comparison and human enzymology.
Schulz-Utermoehl T; Spear M; Pollard CR; Pattison C; Rollison H; Sarda S; Ward M; Bushby N; Jordan A; Harrison M
Drug Metab Dispos; 2010 Oct; 38(10):1688-97. PubMed ID: 20634336
[TBL] [Abstract][Full Text] [Related]
19. Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2.
Marathe P; Tang Y; Sleczka B; Rodrigues D; Gavai A; Wong T; Christopher L; Zhang H
J Pharm Sci; 2010 Aug; 99(8):3579-93. PubMed ID: 20166197
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo metabolism and pharmacokinetics of BMS-562086, a potent and orally bioavailable corticotropin-releasing factor-1 receptor antagonist.
Zhou L; Dockens RC; Liu-Kreyche P; Grossman SJ; Iyer RA
Drug Metab Dispos; 2012 Jun; 40(6):1093-103. PubMed ID: 22381334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
